Could a diabetes drug boost sarcoma treatment?

NCT ID NCT07291297

First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 22 times

Summary

This study tests whether adding metformin, a common diabetes medicine, to standard cancer therapy helps people with advanced soft tissue sarcoma live longer. About 50 adults whose cancer has spread or cannot be removed will receive metformin alongside their first-line treatment. The main goal is to see how many are still alive after 12 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOMA,SOFT TISSUE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center

    RECRUITING

    Winston-Salem, North Carolina, 27103, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Levine Cancer Institute

    RECRUITING

    Charlotte, North Carolina, 28204, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.